RESEARCH USE ONLY. Reference data for laboratory research. Not medical advice; not for human consumption.
Peptijournal
Calc

Compare compounds

Pick up to 3 compounds to see protocols, mechanisms, study endpoints and safety findings side by side.

PopularRetatrutide vs TirzepatideSemaglutide vs TirzepatideSemaglutide vs RetatrutideBPC-157 vs TB-500BPC-157 vs GHK-CuSermorelin vs Tesamorelin
FOXO4-DRI
Same goal
Include when printing

Only affects the printed page / PDF. The research-use-only notice always prints.

Protocol01
FOXO4-DRI

Longevity

Vials · 10 mg

01Protocol

Vials
10 mg
Dosing data
Lab reference — not listed

02Quick calculator

Draw (100u)

—

Concentration

—

mg/mL

03Mechanism of action

FOXO4-DRI is a modified (D-retro-inverso) peptide that disrupts the binding of FOXO4 to p53 in senescent cells, pushing p53 out of the nucleus and triggering apoptosis selectively in those cells (a senolytic).

04Study endpoints

  • In mice, it neutralised doxorubicin-induced toxicity and restored fitness, fur density and kidney function in fast-ageing and naturally aged animals.
  • In keloid tissue and fibroblast models, it promoted apoptosis of senescent fibroblasts.

05Safety & regulatory findings

  • Not approved by the FDA or EMA for any indication; research-grade material is not a medicine.
  • Evidence is from cell and animal studies; no human trials are cited.

06Citations

2 references · view